ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 396-405

  Tachezy, Michael ^a   Effenberger, Katharina ^a   Zander, Hilke ^a   Minner, Sarah ^a   Gebauer, Florian ^a   Vashist, Yogesh K ^a   Sauter, Guido ^a   Pantel, Klaus ^a   Izbicki, Jakob R ^a   Bockhorn, Maximilian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ALCAM; biomarker; esophageal cancer; prognosis

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CYTOKERATIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW METASTASIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; OVERALL SURVIVAL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR VOLUME;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84860653585     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26377     Document Type: Article

References (34)

1. Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, Izbicki JR,. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93: 541-9.
2. Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, Faithova L, Vashist YK, Gawad KA, Baldus SE, Pantel K, Schneider PM, Holscher AH, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 2009; 16: 454-62.
3. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR,. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-7.
4. Hyngstrom JR, Posner MC,. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; 101: 299-304.
5. Barnett SA, Rizk NP,. Randomized clinical trials in esophageal carcinoma. Surg Oncol Clin N Am 2010; 19: 59-80.
6. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-85.
7. Kutup A, Link BC, Schurr PG, Strate T, Kaifi JT, Bubenheim M, Seewald S, Yekebas EF, Soehendra N, Izbicki JR,. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-9.
8. Shimpi RA, George J, Jowell P, Gress FG,. Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointest Endosc 2007; 66: 475-82.
9. Weidle UH, Eggle D, Klostermann S, Swart GW,. ALCAM/CD166: cancer-related issues. Cancer. Genomics. Proteomics 2010; 7: 231-43.
10. Ofori-Acquah SF, King JA,. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008; 151: 122-8.
11. van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC, Swart GW,. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008; 68: 3671-9.
12. Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K,. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112: 419-27.
13. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G,. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57: 1160-4.
14. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008; 14: 1726-33.
15. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009; 101: 457-64.
16. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M,. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5: 1246-53.
17. Weidle UH, Eggle D, Klostermann S,. L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 2009; 29: 4919-31.
18. Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR,. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006; 19: 399-406.
19. Rawnaq T, Kleinhans H, Uto M, Schurr PG, Reichelt U, Cataldegirmen G, Gawad KA, Yekebas EF, Schachner M, Izbicki JR, Kaifi JT,. Subset of esophageal adenocarcinoma expresses adhesion molecule l1 in contrast to squamous cell carcinoma. Anticancer Res 2009; 29: 1195-9.
20. Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S,. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 2009; 24: 2143-8.
21. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP,. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 2009; 125: 9-14.
22. Ladd J, Taylor AD, Piliarik M, Homola J, Jiang S,. Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 2009; 393: 1157-63.
23. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-9.
24. Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Gungor C, Effenberger KE, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki JR, Yekebas EF,. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010; 127: 1931-40.
25. Scheunemann P, Izbicki JR, Pantel K,. Tumorigenic potential of apparently tumor-free lymph nodes. N Engl J Med 1999; 340: 1687.
26. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G,. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I. II, or. III breast cancer. N Engl J Med 2000; 342: 525-33.
27. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, Verde PE, Reichelt U, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 13: 441-53.
28. Altman DG, Lausen B, Sauerbrei W, Schumacher M,. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
29. Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R,. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 2005; 68: 462-70.
30. Wu Y, Zhou BP,. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009; 8: 3267-73.
31. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A,. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54: 34-43.
32. van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC,. Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol 2010; 46: 393-8.
33. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-8.
34. Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K,. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 1996; 88: 1222-7.